Medicare AdvantagePrior AuthMedium impact
Mekinist (trametinib) (Revised)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated prior authorization requirements for Mekinist (trametinib), a cancer medication used for melanoma, lung cancer, thyroid cancer, and other solid tumors. The policy specifies detailed criteria including required genetic mutations (BRAF V600), combination therapy requirements, and specific exclusions for concurrent medications.
Action Required
By January 1, 2026: Clinical staff must ensure all Mekinist (trametinib) prescriptions for Medicare Advantage members meet specific prior authorization criteria including documented BRAF mutations, appropriate diagnosis staging, and combination therapy requirements. Update prior authorization checklists to include genetic testing documentation and exclusion criteria. Claims will be denied without proper prior authorization.